ROCKVILLE, Md.--(BUSINESS WIRE)--BioReliance Corporation announced today that David A. Dodd has been named President, Chief Executive Officer and Chairman of the Board of the Company, effective today. BioReliance Corporation is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide. Avista Capital Partners, a leading private equity firm, acquired BioReliance from Invitrogen (NASDAQ:IVGN) in April 2007.
